Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Lung cancer: Using ctDNA to track EGFR and KRAS mutations in advanced-stage disease.

Literature DB >> 27245284

Lung cancer: Using ctDNA to track EGFR and KRAS mutations in advanced-stage disease.

Rafael Rosell¹, Niki Karachaliou^2,3.

Abstract

Entities: Disease Gene

Mesh：

Substances：

Year: 2016 PMID： 27245284 DOI： 10.1038/nrclinonc.2016.83

Source DB: PubMed Journal: Nat Rev Clin Oncol ISSN： 1759-4774 Impact factor: 66.675

× No keyword cloud information.

10 in total

1. Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer.

Authors: Adrian G Sacher; Cloud Paweletz; Suzanne E Dahlberg; Ryan S Alden; Allison O'Connell; Nora Feeney; Stacy L Mach; Pasi A Jänne; Geoffrey R Oxnard
Journal: JAMA Oncol Date: 2016-08-01 Impact factor: 31.777

2. Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial.

Authors: Niki Karachaliou; Clara Mayo-de las Casas; Cristina Queralt; Itziar de Aguirre; Boris Melloni; Felipe Cardenal; Ramon Garcia-Gomez; Bartomeu Massuti; José Miguel Sánchez; Ruth Porta; Santiago Ponce-Aix; Teresa Moran; Enric Carcereny; Enriqueta Felip; Isabel Bover; Amelia Insa; Noemí Reguart; Dolores Isla; Alain Vergnenegre; Filippo de Marinis; Radj Gervais; Romain Corre; Luis Paz-Ares; Daniela Morales-Espinosa; Santiago Viteri; Ana Drozdowskyj; Núria Jordana-Ariza; Jose Luis Ramirez-Serrano; Miguel Angel Molina-Vila; Rafael Rosell
Journal: JAMA Oncol Date: 2015-05 Impact factor: 31.777

Review 3. Cell-free nucleic acids as biomarkers in cancer patients.

Authors: Heidi Schwarzenbach; Dave S B Hoon; Klaus Pantel
Journal: Nat Rev Cancer Date: 2011-05-12 Impact factor: 60.716

4. The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.

Authors: Matthew J Niederst; Haichuan Hu; Hillary E Mulvey; Elizabeth L Lockerman; Angel R Garcia; Zofia Piotrowska; Lecia V Sequist; Jeffrey A Engelman
Journal: Clin Cancer Res Date: 2015-05-11 Impact factor: 12.531

5. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

Authors: Robert C Doebele; Amanda B Pilling; Dara L Aisner; Tatiana G Kutateladze; Anh T Le; Andrew J Weickhardt; Kimi L Kondo; Derek J Linderman; Lynn E Heasley; Wilbur A Franklin; Marileila Varella-Garcia; D Ross Camidge
Journal: Clin Cancer Res Date: 2012-01-10 Impact factor: 12.531

6. Screening for epidermal growth factor receptor mutations in lung cancer.

Authors: Rafael Rosell; Teresa Moran; Cristina Queralt; Rut Porta; Felipe Cardenal; Carlos Camps; Margarita Majem; Guillermo Lopez-Vivanco; Dolores Isla; Mariano Provencio; Amelia Insa; Bartomeu Massuti; Jose Luis Gonzalez-Larriba; Luis Paz-Ares; Isabel Bover; Rosario Garcia-Campelo; Miguel Angel Moreno; Silvia Catot; Christian Rolfo; Noemi Reguart; Ramon Palmero; José Miguel Sánchez; Roman Bastus; Clara Mayo; Jordi Bertran-Alamillo; Miguel Angel Molina; Jose Javier Sanchez; Miquel Taron
Journal: N Engl J Med Date: 2009-08-19 Impact factor: 91.245

7. Origin and prognostic value of circulating KRAS mutations in lung cancer patients.

Authors: O Gautschi; B Huegli; A Ziegler; M Gugger; J Heighway; D Ratschiller; P C Mack; P H Gumerlock; H J Kung; R A Stahel; D R Gandara; D C Betticher
Journal: Cancer Lett Date: 2007-04-20 Impact factor: 8.679

8. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers.

Authors: Luis A Diaz; Richard T Williams; Jian Wu; Isaac Kinde; J Randolph Hecht; Jordan Berlin; Benjamin Allen; Ivana Bozic; Johannes G Reiter; Martin A Nowak; Kenneth W Kinzler; Kelly S Oliner; Bert Vogelstein
Journal: Nature Date: 2012-06-28 Impact factor: 49.962

9. EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291.

Authors: Kenneth S Thress; Roz Brant; T Hedley Carr; Simon Dearden; Suzanne Jenkins; Helen Brown; Tracey Hammett; Mireille Cantarini; J Carl Barrett
Journal: Lung Cancer Date: 2015-10-09 Impact factor: 5.705

10. Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC.

Authors: A Kalikaki; A Koutsopoulos; M Trypaki; J Souglakos; E Stathopoulos; V Georgoulias; D Mavroudis; A Voutsina
Journal: Br J Cancer Date: 2008-09-16 Impact factor: 7.640

10 in total

12 in total

Review 1. Possible application of circulating free tumor DNA in non-small cell lung cancer patients.

Authors: Niki Karachaliou; Aaron E Sosa; Miguel Angel Molina; Margarita Centelles Ruiz; Rafael Rosell
Journal: J Thorac Dis Date: 2017-10 Impact factor: 2.895

2. Circulating cell-free DNA mutation patterns in early and late stage colon and pancreatic cancer.

Authors: Eveline E Vietsch; Garrett T Graham; Justine N McCutcheon; Aamir Javaid; Giuseppe Giaccone; John L Marshall; Anton Wellstein
Journal: Cancer Genet Date: 2017-09-14

3. Activation of signal transducer and activator of transcription 3 (STAT3) signaling in EGFR mutant non-small-cell lung cancer (NSCLC).

Authors: Carles Codony-Servat; Jordi Codony-Servat; Niki Karachaliou; Miguel Angel Molina; Imane Chaib; Jose Luis Ramirez; Maria de Los Llanos Gil; Flavio Solca; Trever G Bivona; Rafael Rosell
Journal: Oncotarget Date: 2017-07-18

4. Statistical analysis of mutant allele frequency level of circulating cell-free DNA and blood cells in healthy individuals.

Authors: Ligang Xia; Zhoufang Li; Bo Zhou; Geng Tian; Lidong Zeng; Hongyu Dai; Xiaohua Li; Chaoyu Liu; Shixin Lu; Feiyue Xu; Xiaonian Tu; Fang Deng; Yuancai Xie; Weiren Huang; Jiankui He
Journal: Sci Rep Date: 2017-08-08 Impact factor: 4.379

5. Dynamic changes of circulating tumour DNA in surgical lung cancer patients: protocol for a prospective observational study.

Authors: Kezhong Chen; Heng Zhao; Fan Yang; Bengang Hui; Tianyang Wang; Lieu Tu Wang; Yanbin Shi; Jun Wang
Journal: BMJ Open Date: 2018-02-06 Impact factor: 2.692

6. Identifying Circulating Tumor DNA Mutation Profiles in Metastatic Breast Cancer Patients with Multiline Resistance.

Authors: Zhe-Yu Hu; Ning Xie; Can Tian; Xiaohong Yang; Liping Liu; Jing Li; Huawu Xiao; Hui Wu; Jun Lu; Jianxiang Gao; Xuming Hu; Min Cao; Zhengrong Shui; Mengjia Xiao; Yu Tang; Qiongzhi He; Lianpeng Chang; Xuefeng Xia; Xin Yi; Qianjin Liao; Quchang Ouyang
Journal: EBioMedicine Date: 2018-05-26 Impact factor: 8.143

7. Ultra-Low DNA Input into Whole Genome Methylation Assays and Detection of Oncogenic Methylation and Copy Number Variants in Circulating Tumour DNA.

Authors: Paul Nankivell; Andrew D Beggs; Celina Whalley; Karl Payne; Enric Domingo; Andrew Blake; Susan Richman; Jill Brooks; Nikolaos Batis; Rachel Spruce; Hisham Mehanna
Journal: Epigenomes Date: 2021-02-19

8. ZNF251 promotes the progression of lung cancer by activating ERK signaling.

Authors: Chenxi Zhong; Chunji Chen; Feng Yao; Wentao Fang
Journal: Cancer Sci Date: 2020-07-15 Impact factor: 6.716

Review 9. Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy.

Authors: Mariacarmela Santarpia; Alessia Liguori; Niki Karachaliou; Maria Gonzalez-Cao; Maria Grazia Daffinà; Alessandro D'Aveni; Grazia Marabello; Giuseppe Altavilla; Rafael Rosell
Journal: Lung Cancer (Auckl) Date: 2017-08-18

10. A Cost-Effective and Non-Invasive pfeRNA-Based Test Differentiates Benign and Suspicious Pulmonary Nodules from Malignant Ones.

Authors: Wei Liu; Yuyan Wang; Hongchan Huang; Nadege Fackche; Kristen Rodgers; Beverly Lee; Wasay Nizam; Hamza Khan; Zhihao Lu; Xiangqian Kong; Yanfei Li; Naixin Liang; Xin Zhao; Xin Jin; Haibo Liu; Charles Conover Talbot; Peng Huang; James R Eshleman; Qi Lai; Yi Zhang; Malcolm V Brock; Yuping Mei
Journal: Noncoding RNA Date: 2021-12-16